Trial
NCT02717949
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Memorial Sloan Kettering Cancer Center; Weill Medical College of Cornell University
Condition
Liver Disease
Intervention
sofosbuvir/ledipasvir
Why stopped
failure to recruit
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-08